<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02262871</url>
  </required_header>
  <id_info>
    <org_study_id>REB14-338</org_study_id>
    <nct_id>NCT02262871</nct_id>
  </id_info>
  <brief_title>HFN Versus NIV in Cystic Fibrosis. The HIFEN Study</brief_title>
  <official_title>Randomized Cross-over Physiologic Study of High Flow Nasal Oxygen Cannula Versus Non-invasive Ventilation in Cystic Fibrosis. The HIFEN Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Unity Health Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many patients with cystic fibrosis (CF) require hospitalization and/or Intensive Care Unit&#xD;
      (ICU) admission because of acute exacerbation of chronic respiratory failure or for any acute&#xD;
      deterioration of clinical status. Non-invasive ventilation (NIV) is the first option for the&#xD;
      clinical management of CF patients with moderate-to-severe respiratory distress and NIV has&#xD;
      been shown to improve gas exchange, reduce respiratory muscle work and improve pulmonary&#xD;
      function in patients with obstructive lung disease in general and those with acute CF&#xD;
      exacerbation. High-flow nasal oxygen cannula (HFN) is a relatively new system providing&#xD;
      heated and humidified, high-flow (50L/min) oxygen through the nostrils. This device provides&#xD;
      a small positive pressure, probably washes-out the pharyngeal dead space, reduces inspiratory&#xD;
      resistance, and possibly facilitates secretion clearance. The technique is very well&#xD;
      tolerated. From a physiologic standpoint, this device could help CF patients by improving gas&#xD;
      exchange, reducing respiratory workload, and facilitating mucus clearance. Non-interrupted&#xD;
      delivery may be possible given better clinical tolerance in contrast with bi-level positive&#xD;
      pressure NIV. Whether the short-term physiological efficacy of HFN is comparable to NIV is&#xD;
      unknown and there is no study on the benefit of HFN in CF patients.&#xD;
&#xD;
      The aim of this study is to compare the physiological effects of HFN and NIV in CF patients&#xD;
      requiring ventilatory support. Our hypothesis is that HFN will not be inferior to NIV, as&#xD;
      evaluated by breathing pattern, gas exchange, and respiratory workload and will decrease dead&#xD;
      space. In addition, comfort and preference between the two techniques will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">July 30, 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The decrease of diaphragmatic workload (thickening fraction of the diaphragm)</measure>
    <time_frame>30 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory parameters</measure>
    <time_frame>30 minutes</time_frame>
    <description>respiratory rate (RR), minute ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gas exchange</measure>
    <time_frame>30 minutes</time_frame>
    <description>pulse oximetry, transcutaneous carbon dioxide partial pressure (PCO2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electromyographic activity of the diaphragm</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>CF patients HFN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CF patients who meet the eligibility criteria will be randomized to receive HFN and then crossover to other device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CF patients NIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CF patients who meet the eligibility criteria will be randomized to receive NIV and then crossover to other device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High flow nasal oxygen cannula</intervention_name>
    <description>HFN will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) will be adjusted to achieve an oxygen saturation (SpO2) of at least 92%.</description>
    <arm_group_label>CF patients HFN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Noninvasive ventilation</intervention_name>
    <description>The setting of NIV will be appropriately adjusted, based on the clinical assessment of the respiratory therapist in charge and will not be modified during the test.</description>
    <arm_group_label>CF patients NIV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Cystic fibrosis as defined by clinical features in conjunction with 2 CF causing&#xD;
             mutations and/or 2 sweat tests with sweat chloride &gt; 60 mmol/l&#xD;
&#xD;
          -  Clinical indication for NIV based on at least one of the following criteria:&#xD;
&#xD;
               -  Signs of clinical respiratory distress - RR &gt; 24/min, accessory muscle use, or&#xD;
                  increased dyspnea&#xD;
&#xD;
               -  Progressive increase in arterial PCO2&#xD;
&#xD;
               -  Nocturnal hypoventilation treated by NIV but requiring daytime NIV because of&#xD;
                  clinical worsening&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Active massive hemoptysis&#xD;
&#xD;
          -  Pneumothorax with pleural drainage and persistent air leak&#xD;
&#xD;
          -  Hemodynamic instability requiring vasopressors&#xD;
&#xD;
          -  Uncooperative&#xD;
&#xD;
          -  Recent upper airway or esophageal surgery&#xD;
&#xD;
          -  Patients with skin or chest wall or abdominal trauma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Brochard, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unity Health Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Roca O, Riera J, Torres F, Masclans JR. High-flow oxygen therapy in acute respiratory failure. Respir Care. 2010 Apr;55(4):408-13.</citation>
    <PMID>20406507</PMID>
  </reference>
  <results_reference>
    <citation>Davies JC, Alton EW, Bush A. Cystic fibrosis. BMJ. 2007 Dec 15;335(7632):1255-9. doi: 10.1136/bmj.39391.713229.AD. No abstract available.</citation>
    <PMID>18079549</PMID>
  </results_reference>
  <results_reference>
    <citation>Pittman JE, Cutting G, Davis SD, Ferkol T, Boucher R. Cystic fibrosis: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc. 2014 Apr;11 Suppl 3(Suppl 3):S161-8. doi: 10.1513/AnnalsATS.201312-444LD.</citation>
    <PMID>24754825</PMID>
  </results_reference>
  <results_reference>
    <citation>Flume PA. Pulmonary complications of cystic fibrosis. Respir Care. 2009 May;54(5):618-27. doi: 10.4187/aarc0443.</citation>
    <PMID>19393106</PMID>
  </results_reference>
  <results_reference>
    <citation>Nick JA, Chacon CS, Brayshaw SJ, Jones MC, Barboa CM, St Clair CG, Young RL, Nichols DP, Janssen JS, Huitt GA, Iseman MD, Daley CL, Taylor-Cousar JL, Accurso FJ, Saavedra MT, Sontag MK. Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. Am J Respir Crit Care Med. 2010 Sep 1;182(5):614-26. doi: 10.1164/rccm.201001-0092OC. Epub 2010 May 6.</citation>
    <PMID>20448091</PMID>
  </results_reference>
  <results_reference>
    <citation>Belkin RA, Henig NR, Singer LG, Chaparro C, Rubenstein RC, Xie SX, Yee JY, Kotloff RM, Lipson DA, Bunin GR. Risk factors for death of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med. 2006 Mar 15;173(6):659-66. doi: 10.1164/rccm.200410-1369OC. Epub 2005 Dec 30.</citation>
    <PMID>16387803</PMID>
  </results_reference>
  <results_reference>
    <citation>Sood N, Paradowski LJ, Yankaskas JR. Outcomes of intensive care unit care in adults with cystic fibrosis. Am J Respir Crit Care Med. 2001 Feb;163(2):335-8. doi: 10.1164/ajrccm.163.2.2003076.</citation>
    <PMID>11179102</PMID>
  </results_reference>
  <results_reference>
    <citation>Jones A, Bilton D, Evans TW, Finney SJ. Predictors of outcome in patients with cystic fibrosis requiring endotracheal intubation. Respirology. 2013 May;18(4):630-6. doi: 10.1111/resp.12051.</citation>
    <PMID>23323684</PMID>
  </results_reference>
  <results_reference>
    <citation>Fauroux B, Burgel PR, Boelle PY, Cracowski C, Murris-Espin M, Nove-Josserand R, Stremler N, Derlich L, Giovanetti P, Clement A; Chronic Respiratory Insufficiency Group of the French National Cystic Fibrosis Federation. Practice of noninvasive ventilation for cystic fibrosis: a nationwide survey in France. Respir Care. 2008 Nov;53(11):1482-9.</citation>
    <PMID>18957151</PMID>
  </results_reference>
  <results_reference>
    <citation>Fauroux B. Why, when and how to propose noninvasive ventilation in cystic fibrosis? Minerva Anestesiol. 2011 Nov;77(11):1108-14. Epub 2011 May 20.</citation>
    <PMID>21602746</PMID>
  </results_reference>
  <results_reference>
    <citation>Madden BP, Kariyawasam H, Siddiqi AJ, Machin A, Pryor JA, Hodson ME. Noninvasive ventilation in cystic fibrosis patients with acute or chronic respiratory failure. Eur Respir J. 2002 Feb;19(2):310-3. doi: 10.1183/09031936.02.00218502. Erratum In: Eur Respir J. 2002 Sep;20(3):790.</citation>
    <PMID>11866011</PMID>
  </results_reference>
  <results_reference>
    <citation>Fauroux B, Nicot F, Essouri S, Hart N, Clement A, Polkey MI, Lofaso F. Setting of noninvasive pressure support in young patients with cystic fibrosis. Eur Respir J. 2004 Oct;24(4):624-30. doi: 10.1183/09031936.04.0000137603.</citation>
    <PMID>15459142</PMID>
  </results_reference>
  <results_reference>
    <citation>Granton JT, Kesten S. The acute effects of nasal positive pressure ventilation in patients with advanced cystic fibrosis. Chest. 1998 Apr;113(4):1013-8. doi: 10.1378/chest.113.4.1013.</citation>
    <PMID>9554640</PMID>
  </results_reference>
  <results_reference>
    <citation>Serra A, Polese G, Braggion C, Rossi A. Non-invasive proportional assist and pressure support ventilation in patients with cystic fibrosis and chronic respiratory failure. Thorax. 2002 Jan;57(1):50-4. doi: 10.1136/thorax.57.1.50.</citation>
    <PMID>11809990</PMID>
  </results_reference>
  <results_reference>
    <citation>Young AC, Wilson JW, Kotsimbos TC, Naughton MT. Randomised placebo controlled trial of non-invasive ventilation for hypercapnia in cystic fibrosis. Thorax. 2008 Jan;63(1):72-7. doi: 10.1136/thx.2007.082602. Epub 2007 Aug 3.</citation>
    <PMID>17675317</PMID>
  </results_reference>
  <results_reference>
    <citation>Ricard JD. High flow nasal oxygen in acute respiratory failure. Minerva Anestesiol. 2012 Jul;78(7):836-41. Epub 2012 Apr 24.</citation>
    <PMID>22531566</PMID>
  </results_reference>
  <results_reference>
    <citation>Cuquemelle E, Pham T, Papon JF, Louis B, Danin PE, Brochard L. Heated and humidified high-flow oxygen therapy reduces discomfort during hypoxemic respiratory failure. Respir Care. 2012 Oct;57(10):1571-7. doi: 10.4187/respcare.01681. Epub 2012 Mar 12.</citation>
    <PMID>22417569</PMID>
  </results_reference>
  <results_reference>
    <citation>Corley A, Caruana LR, Barnett AG, Tronstad O, Fraser JF. Oxygen delivery through high-flow nasal cannulae increase end-expiratory lung volume and reduce respiratory rate in post-cardiac surgical patients. Br J Anaesth. 2011 Dec;107(6):998-1004. doi: 10.1093/bja/aer265. Epub 2011 Sep 9.</citation>
    <PMID>21908497</PMID>
  </results_reference>
  <results_reference>
    <citation>Rittayamai N, Tscheikuna J, Rujiwit P. High-flow nasal cannula versus conventional oxygen therapy after endotracheal extubation: a randomized crossover physiologic study. Respir Care. 2014 Apr;59(4):485-90. doi: 10.4187/respcare.02397. Epub 2013 Sep 17.</citation>
    <PMID>24046462</PMID>
  </results_reference>
  <results_reference>
    <citation>Maggiore SM, Idone FA, Vaschetto R, Festa R, Cataldo A, Antonicelli F, Montini L, De Gaetano A, Navalesi P, Antonelli M. Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. Am J Respir Crit Care Med. 2014 Aug 1;190(3):282-8. doi: 10.1164/rccm.201402-0364OC.</citation>
    <PMID>25003980</PMID>
  </results_reference>
  <results_reference>
    <citation>Matamis D, Soilemezi E, Tsagourias M, Akoumianaki E, Dimassi S, Boroli F, Richard JC, Brochard L. Sonographic evaluation of the diaphragm in critically ill patients. Technique and clinical applications. Intensive Care Med. 2013 May;39(5):801-10. doi: 10.1007/s00134-013-2823-1. Epub 2013 Jan 24.</citation>
    <PMID>23344830</PMID>
  </results_reference>
  <results_reference>
    <citation>Vivier E, Mekontso Dessap A, Dimassi S, Vargas F, Lyazidi A, Thille AW, Brochard L. Diaphragm ultrasonography to estimate the work of breathing during non-invasive ventilation. Intensive Care Med. 2012 May;38(5):796-803. doi: 10.1007/s00134-012-2547-7. Epub 2012 Apr 5.</citation>
    <PMID>22476448</PMID>
  </results_reference>
  <results_reference>
    <citation>Vignaux L, Vargas F, Roeseler J, Tassaux D, Thille AW, Kossowsky MP, Brochard L, Jolliet P. Patient-ventilator asynchrony during non-invasive ventilation for acute respiratory failure: a multicenter study. Intensive Care Med. 2009 May;35(5):840-6. doi: 10.1007/s00134-009-1416-5. Epub 2009 Jan 29.</citation>
    <PMID>19183949</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>October 7, 2014</study_first_submitted>
  <study_first_submitted_qc>October 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2014</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic fibrosis</keyword>
  <keyword>High-flow nasal oxygen cannula</keyword>
  <keyword>Non-invasive ventilation</keyword>
  <keyword>Respiratory distress</keyword>
  <keyword>Oxygen therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02262871
org study id: REB14-338
nct id: NCT02262871
lead sponsor: 
has dmc: No
Many patients with cystic fibrosis (CF) require hospitalization and/or Intensive Care Unit
      (ICU) admission because of acute exacerbation of chronic respiratory failure or for any acute
      deterioration of clinical status. Non-invasive ventilation (NIV) is the first option for the
      clinical management of CF patients with moderate-to-severe respiratory distress and NIV has
      been shown to improve gas exchange, reduce respiratory muscle work and improve pulmonary
      function in patients with obstructive lung disease in general and those with acute CF
      exacerbation. High-flow nasal oxygen cannula (HFN) is a relatively new system providing
      heated and humidified, high-flow (50L/min) oxygen through the nostrils. This device provides
      a small positive pressure, probably washes-out the pharyngeal dead space, reduces inspiratory
      resistance, and possibly facilitates secretion clearance. The technique is very well
      tolerated. From a physiologic standpoint, this device could help CF patients by improving gas
      exchange, reducing respiratory workload, and facilitating mucus clearance. Non-interrupted
      delivery may be possible given better clinical tolerance in contrast with bi-level positive
      pressure NIV. Whether the short-term physiological efficacy of HFN is comparable to NIV is
      unknown and there is no study on the benefit of HFN in CF patients.

      The aim of this study is to compare the physiological effects of HFN and NIV in CF patients
      requiring ventilatory support. Our hypothesis is that HFN will not be inferior to NIV, as
      evaluated by breathing pattern, gas exchange, and respiratory workload and will decrease dead
      space. In addition, comfort and preference between the two techniques will be evaluated.
allocation: Randomized
intervention model: Crossover Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: The decrease of diaphragmatic workload (thickening fraction of the diaphragm)
time frame: 30 minutes
measure: Respiratory parameters
time frame: 30 minutes
description: respiratory rate (RR), minute ventilation
measure: Gas exchange
time frame: 30 minutes
description: pulse oximetry, transcutaneous carbon dioxide partial pressure (PCO2)
measure: Electromyographic activity of the diaphragm
time frame: 30 minutes
arm group label: CF patients HFN
arm group type: Experimental
description: CF patients who meet the eligibility criteria will be randomized to receive HFN and then crossover to other device.
arm group label: CF patients NIV
arm group type: Experimental
description: CF patients who meet the eligibility criteria will be randomized to receive NIV and then crossover to other device.
intervention type: Device
intervention name: High flow nasal oxygen cannula
description: HFN will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) will be adjusted to achieve an oxygen saturation (SpO2) of at least 92%.
arm group label: CF patients HFN
intervention type: Device
intervention name: Noninvasive ventilation
description: The setting of NIV will be appropriately adjusted, based on the clinical assessment of the respiratory therapist in charge and will not be modified during the test.
arm group label: CF patients NIV
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Laurent Brochard, Dr.
role: Principal Investigator
affiliation: Unity Health Toronto
facility: 
country: Canada
citation: Roca O, Riera J, Torres F, Masclans JR. High-flow oxygen therapy in acute respiratory failure. Respir Care. 2010 Apr;55(4):408-13.
PMID: 20406507
citation: Davies JC, Alton EW, Bush A. Cystic fibrosis. BMJ. 2007 Dec 15;335(7632):1255-9. doi: 10.1136/bmj.39391.713229.AD. No abstract available.
PMID: 18079549
citation: Pittman JE, Cutting G, Davis SD, Ferkol T, Boucher R. Cystic fibrosis: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc. 2014 Apr;11 Suppl 3(Suppl 3):S161-8. doi: 10.1513/AnnalsATS.201312-444LD.
PMID: 24754825
citation: Flume PA. Pulmonary complications of cystic fibrosis. Respir Care. 2009 May;54(5):618-27. doi: 10.4187/aarc0443.
PMID: 19393106
citation: Nick JA, Chacon CS, Brayshaw SJ, Jones MC, Barboa CM, St Clair CG, Young RL, Nichols DP, Janssen JS, Huitt GA, Iseman MD, Daley CL, Taylor-Cousar JL, Accurso FJ, Saavedra MT, Sontag MK. Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. Am J Respir Crit Care Med. 2010 Sep 1;182(5):614-26. doi: 10.1164/rccm.201001-0092OC. Epub 2010 May 6.
PMID: 20448091
citation: Belkin RA, Henig NR, Singer LG, Chaparro C, Rubenstein RC, Xie SX, Yee JY, Kotloff RM, Lipson DA, Bunin GR. Risk factors for death of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med. 2006 Mar 15;173(6):659-66. doi: 10.1164/rccm.200410-1369OC. Epub 2005 Dec 30.
PMID: 16387803
citation: Sood N, Paradowski LJ, Yankaskas JR. Outcomes of intensive care unit care in adults with cystic fibrosis. Am J Respir Crit Care Med. 2001 Feb;163(2):335-8. doi: 10.1164/ajrccm.163.2.2003076.
PMID: 11179102
citation: Jones A, Bilton D, Evans TW, Finney SJ. Predictors of outcome in patients with cystic fibrosis requiring endotracheal intubation. Respirology. 2013 May;18(4):630-6. doi: 10.1111/resp.12051.
PMID: 23323684
citation: Fauroux B, Burgel PR, Boelle PY, Cracowski C, Murris-Espin M, Nove-Josserand R, Stremler N, Derlich L, Giovanetti P, Clement A; Chronic Respiratory Insufficiency Group of the French National Cystic Fibrosis Federation. Practice of noninvasive ventilation for cystic fibrosis: a nationwide survey in France. Respir Care. 2008 Nov;53(11):1482-9.
PMID: 18957151
citation: Fauroux B. Why, when and how to propose noninvasive ventilation in cystic fibrosis? Minerva Anestesiol. 2011 Nov;77(11):1108-14. Epub 2011 May 20.
PMID: 21602746
citation: Madden BP, Kariyawasam H, Siddiqi AJ, Machin A, Pryor JA, Hodson ME. Noninvasive ventilation in cystic fibrosis patients with acute or chronic respiratory failure. Eur Respir J. 2002 Feb;19(2):310-3. doi: 10.1183/09031936.02.00218502. Erratum In: Eur Respir J. 2002 Sep;20(3):790.
PMID: 11866011
citation: Fauroux B, Nicot F, Essouri S, Hart N, Clement A, Polkey MI, Lofaso F. Setting of noninvasive pressure support in young patients with cystic fibrosis. Eur Respir J. 2004 Oct;24(4):624-30. doi: 10.1183/09031936.04.0000137603.
PMID: 15459142
citation: Granton JT, Kesten S. The acute effects of nasal positive pressure ventilation in patients with advanced cystic fibrosis. Chest. 1998 Apr;113(4):1013-8. doi: 10.1378/chest.113.4.1013.
PMID: 9554640
citation: Serra A, Polese G, Braggion C, Rossi A. Non-invasive proportional assist and pressure support ventilation in patients with cystic fibrosis and chronic respiratory failure. Thorax. 2002 Jan;57(1):50-4. doi: 10.1136/thorax.57.1.50.
PMID: 11809990
citation: Young AC, Wilson JW, Kotsimbos TC, Naughton MT. Randomised placebo controlled trial of non-invasive ventilation for hypercapnia in cystic fibrosis. Thorax. 2008 Jan;63(1):72-7. doi: 10.1136/thx.2007.082602. Epub 2007 Aug 3.
PMID: 17675317
citation: Ricard JD. High flow nasal oxygen in acute respiratory failure. Minerva Anestesiol. 2012 Jul;78(7):836-41. Epub 2012 Apr 24.
PMID: 22531566
citation: Cuquemelle E, Pham T, Papon JF, Louis B, Danin PE, Brochard L. Heated and humidified high-flow oxygen therapy reduces discomfort during hypoxemic respiratory failure. Respir Care. 2012 Oct;57(10):1571-7. doi: 10.4187/respcare.01681. Epub 2012 Mar 12.
PMID: 22417569
citation: Corley A, Caruana LR, Barnett AG, Tronstad O, Fraser JF. Oxygen delivery through high-flow nasal cannulae increase end-expiratory lung volume and reduce respiratory rate in post-cardiac surgical patients. Br J Anaesth. 2011 Dec;107(6):998-1004. doi: 10.1093/bja/aer265. Epub 2011 Sep 9.
PMID: 21908497
citation: Rittayamai N, Tscheikuna J, Rujiwit P. High-flow nasal cannula versus conventional oxygen therapy after endotracheal extubation: a randomized crossover physiologic study. Respir Care. 2014 Apr;59(4):485-90. doi: 10.4187/respcare.02397. Epub 2013 Sep 17.
PMID: 24046462
citation: Maggiore SM, Idone FA, Vaschetto R, Festa R, Cataldo A, Antonicelli F, Montini L, De Gaetano A, Navalesi P, Antonelli M. Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. Am J Respir Crit Care Med. 2014 Aug 1;190(3):282-8. doi: 10.1164/rccm.201402-0364OC.
PMID: 25003980
citation: Matamis D, Soilemezi E, Tsagourias M, Akoumianaki E, Dimassi S, Boroli F, Richard JC, Brochard L. Sonographic evaluation of the diaphragm in critically ill patients. Technique and clinical applications. Intensive Care Med. 2013 May;39(5):801-10. doi: 10.1007/s00134-013-2823-1. Epub 2013 Jan 24.
PMID: 23344830
citation: Vivier E, Mekontso Dessap A, Dimassi S, Vargas F, Lyazidi A, Thille AW, Brochard L. Diaphragm ultrasonography to estimate the work of breathing during non-invasive ventilation. Intensive Care Med. 2012 May;38(5):796-803. doi: 10.1007/s00134-012-2547-7. Epub 2012 Apr 5.
PMID: 22476448
citation: Vignaux L, Vargas F, Roeseler J, Tassaux D, Thille AW, Kossowsky MP, Brochard L, Jolliet P. Patient-ventilator asynchrony during non-invasive ventilation for acute respiratory failure: a multicenter study. Intensive Care Med. 2009 May;35(5):840-6. doi: 10.1007/s00134-009-1416-5. Epub 2009 Jan 29.
PMID: 19183949
responsible party type: Sponsor
mesh term: Cystic Fibrosis
mesh term: Fibrosis